People with diabetes, particularly severe diabetes, tend to lose less weight with GLP-1s than people without diabetes, so microdosing is less likely to be as effective, though their dose should only be increased as they tolerate it. George said that in her professional opinion, microdosing is a potential option for patients with smaller amounts of weight to lose or as a bridge to start, or wean off, regular GLP-1 medications
Common denial reasons are plan exclusion for weight loss medications, non-formulary for your medication, or need for prior diet and exercise program
Nausea and vomiting are less frequent in patients receiving EX-LAR than in patients taking EX (114)
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, et al
Because the medication goes straight into your system, the effects are consistent and predictable, which is why these injections have such strong clinical evidence behind them
Some subscription programs, like Lemme GLP-1, use compounding pharmacies that may not meet FDA safety standards
